Patent intelligence · US
US 10391095
DNA-PK inhibitors
DNA-PK inhibitors
Patent details — US 10391095
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 27, 2019
- Expiration
- Aug 22, 2039
- Applicant
- Vertex Pharmaceuticals Incorporated
- Claims
- 9
- CPC classes
- A61K, A61K31/506, A61K31/53, A61K31/5377
Quick answer
US 10391095 (DNA-PK inhibitors) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Aug 27, 2019. Expires Aug 22, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Vertex Pharmaceuticals Incorporated
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/506, A61K31/53, A61K31/5377, A61K41/0038, A61K47/545
More from Vertex Pharmaceuticals Incorporated
Related pharmaceutical patents in our USPTO index.
-
US 12421251
Cystic fibrosis transmembrane conductance regulator modulating agents
granted -
US 12421249
Inhibitors of APOL1 and methods of using same
granted -
US 12384790
Pteridinone compounds and uses thereof
granted -
US 12384762
Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
granted -
US 12385013
Differentiation of pancreatic endocrine cells
granted -
US 12377252
Implantation devices, system, and methods
granted -
US 12371665
Differentiation of pancreatic endocrine cells
granted -
US 12350262
Methods of treatment for cystic fibrosis
granted
Frequently asked questions
What is US patent 10391095?
US 10391095 (DNA-PK inhibitors) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Aug 27, 2019. Expires Aug 22, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10391095?
Vertex Pharmaceuticals Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 991 pharmaceutical patents for this assignee.
When does US 10391095 expire?
Our index shows an expiration date of Aug 22, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.